Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun;30(7):899-924.
doi: 10.1177/13524585231223880. Epub 2024 Feb 15.

Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society

Nicolas Collongues  1   2   3   4 , Françoise Durand-Dubief  5 , Christine Lebrun-Frenay  6   7 , Bertrand Audoin  8 , Xavier Ayrignac  9   10   11 , Caroline Bensa  12 , Kévin Bigaut  1   3 , Bertrand Bourre  13 , Clarisse Carra-Dallière  9 , Jonathan Ciron  14   15 , Gilles Defer  16 , Arnaud Kwiatkowski  17 , Emmanuelle Leray  18 , Elisabeth Maillart  19 , Romain Marignier  5 , Guillaume Mathey  20 , Nathalie Morel  21 , Eric Thouvenot  22   23 , Hélène Zéphir  24 , Julie Boucher  25 , Clémence Boutière  26 , Pierre Branger  27 , Angélique Da Silva  28 , Sarah Demortière  8 , Maxime Guillaume  13 , Benjamin Hebant  13 , Edouard Januel  29   30 , Anne Kerbrat  31   32 , Eric Manchon  33 , Xavier Moisset  34 , Alexis Montcuquet  35 , Chloé Pierret  36 , Julie Pique  5 , Julien Poupart  37 , Chloé Prunis  20 , Thomas Roux  38   39 , Perrine Schmitt  22 , Géraldine Androdias  40   41 , Mikael Cohen  42
Affiliations
Review

Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society

Nicolas Collongues et al. Mult Scler. 2024 Jun.

Abstract

Background: Epidemiological data reveal that 45% of persons with multiple sclerosis (PwMS) in France are more than 50 years. This population more than 50 is more susceptible to cancer, and this risk may be increased by frequent use of immunosuppressive drugs. Consequently, concerns have arisen about the potential increased risk of cancer in PwMS and how patients should be screened and managed in terms of cancer risk.

Objective: To develop evidence-based recommendations to manage the coexistence of cancer and multiple sclerosis (MS).

Methods: The French Group for Recommendations in MS collected articles from PubMed and university databases covering the period January 1975 through June 2022. The RAND/UCLA method was employed to achieve formal consensus. MS experts comprehensively reviewed the full-text articles and developed the initial recommendations. A group of multidisciplinary health care specialists then validated the final proposal.

Results: Five key questions were addressed, encompassing various topics such as cancer screening before or after initiating a disease-modifying therapy (DMT), appropriate management of MS in the context of cancer, recommended follow-up for cancer in patients receiving a DMT, and the potential reintroduction of a DMT after initial cancer treatment. A strong consensus was reached for all 31 recommendations.

Conclusion: These recommendations propose a strategic approach to managing cancer risk in PwMS.

Keywords: Multiple sclerosis; cancer; checkpoint inhibitors; disease-modifying treatments; immunotherapy.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: N. Collongues has received honoraria for consulting or presentation from Alexion, Biogen Idec, Bristol-Myers Squibb, Horizon Therapeutics, Merck Serono, Novartis, Roche, and Sanofi-Genzyme and is a member of the Editorial Board of the Journal de la Ligue Française contre la Sclérose en plaques and the Neurology and Therapy Journal. Françoise Durand-Dubief has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities from Biogen, BMS-Celgene, Merck, Novartis, Roche, Sanofi-Genzyme, and Teva. Christine Lebrun Frenay has nothing to disclose. Géraldine Androdias has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities from Biogen, Merck, Novartis, Roche, and Sanofi-Genzyme. Bertrand Audoin has nothing to disclose. Xavier Ayrignac has received consulting fees and lecturing fess, travel grants, and unconditional research support from Alexion, Biogen, Genzyme, Janssen, Merck Serono, Novartis, Roche, Sanofi Aventis, and Teva Pharma. Caroline Bensa has received consulting honoraria from Alexion, Sanofi, Merck, Biogen, BMS, and Novartis. Kevin Bigaut has received lecturing fees and travel grants from Biogen, Celgene-BMS, Novartis, Roche, and Sanofi-Genzyme. Julie Boucher has nothing to disclose. Bertrand Bourre serves on the scientific advisory board and has received funding for travel and honoraria from Alexion, Biogen, BMS, Horizon, Janssen, Merck, Novartis, Sanofi, and Roche. Clemence Boutiere has nothing to disclose. Pierre Branger has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities from Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, and Sanofi-Genzyme. C. Carra-Dalliere has received travel grants and/or consulting fees from Alexion, Biogen, Merck, Novartis, Roche, and Sanofi-Genzyme. Jonathan Ciron has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities from Biogen, Novartis, Merck, Sanofi, Roche, Celgene-BMS, Alexion, and Horizon Therapeutics. Angelique Da Silva has received personal fees from Daichi and Leopharma. Gilles Defer has received personal fees from Biogen, Bristol-Myers Squibb, Merck Serono, Novartis, Sanofi-Genzyme, and Teva Pharmaceuticals. Sarah Demortière has nothing to disclose. Maxime Guillaume has received honoraria from Novartis, Merck, and Sanofi. Benjamin Hebant has nothing to disclose. Edouard Januel has nothing to disclose. Anne Kerbrat has nothing to disclose. Arnaud Kwiatkowski has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities from Biogen, Merck Serono, Novartis, Sanofi-Genzyme, Roche, and Teva. Emmanuelle Leray has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alexion, Biogen, Merck, Novartis, Roche, and Sanofi-Genzyme. Elisabeth Maillart has received research support from Biogen and personal fees for lectures and serving on advisory boards from Biogen, Janssen, Merck, Novartis, Roche, Sanofi, and Teva. Guillaume Mathey has nothing to disclose. Xavier Moisset has received financial support from Allergan-Abbvie, Biogen, BMS, Grünenthal, Lilly, Lundbeck, Teva, Merck Serono, Novartis, Pfizer, Roche, and Sanofi-Genzyme and non-financial support from SOS Oxygène not related to the submitted work. Alexis Montcuquet has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities from Alexison, Biogen, Merck Serono, Novartis, Sanofi-Genzyme, Roche, and Teva. Nathalie Morel has nothing to disclose. Romain Marignier has received personal fees from Horizon Therapeutics, Alexion, Roche, and UCB; and nonfinancial support from Horizon Therapeutics, Merck, Biogen, and Roche. Chloe Pierret has nothing to disclose. Julie Pique has received travel grants and personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities from Teva, Biogen, Novartis, Merck, Sanofi-Genzyme, Roche, Celgene-BMS, and Alexion. Julien Poupart has nothing to disclose. Chloe Prunis has nothing to disclose. Eric Thouvenot has received personal fees from Actelion and Teva and grants from Biogen, Merck Serono, Novartis, and Roche. Thomas Roux has received personal compensation for consulting, speaking, or serving on a scientific advisory board from Alexion, Biogen, BMS-Celgene, Merck, Novartis, and Sanofi-Genzyme. Perrine Schmitt has nothing to disclose. Helene Zephir has nothing to disclose. Mikael Cohen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities from Ad Scientiam, Biogen, Merck, Sanofi-Genzyme, Roche, Celgene-BMS, Alexion, and Horizon Therapeutics.

Similar articles

  • Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis society.
    Vukusic S, Carra-Dalliere C, Ciron J, Maillart E, Michel L, Leray E, Guennoc AM, Bourre B, Laplaud D, Androdias G, Bensa C, Bigaut K, Biotti D, Branger P, Casez O, Cohen M, Daval E, Deschamps R, Donze C, Dubessy AL, Dulau C, Durand-Dubief F, Guillaume M, Hebant B, Kremer L, Kwiatkowski A, Lannoy J, Maarouf A, Manchon E, Mathey G, Moisset X, Montcuquet A, Pique J, Roux T, Marignier R, Lebrun-Frenay C. Vukusic S, et al. Mult Scler. 2023 Jan;29(1):11-36. doi: 10.1177/13524585221129472. Epub 2022 Nov 1. Mult Scler. 2023. PMID: 36317497 Review.
  • Infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society.
    Papeix C, Donze C, Lebrun-Frénay C; French Group for Recommendations in Multiple Sclerosis (France4MS), the Société Francophone de la Sclérose En Plaques (SFSEP); Co-Chairs; Group of evaluators Coordinators; Readers; Cotator; Expert readers (voters). Papeix C, et al. Rev Neurol (Paris). 2021 Oct;177(8):980-994. doi: 10.1016/j.neurol.2021.04.011. Epub 2021 Jul 21. Rev Neurol (Paris). 2021. PMID: 34303537
  • Pregnancy and neuromyelitis optica spectrum disorders: 2022 recommendations from the French Multiple Sclerosis Society.
    Vukusic S, Marignier R, Ciron J, Bourre B, Cohen M, Deschamps R, Guillaume M, Kremer L, Pique J, Carra-Dalliere C, Michel L, Leray E, Guennoc AM, Laplaud D, Androdias G, Bensa C, Bigaut K, Biotti D, Branger P, Casez O, Daval E, Donze C, Dubessy AL, Dulau C, Durand-Dubief F, Hebant B, Kwiatkowski A, Lannoy J, Maarouf A, Manchon E, Mathey G, Moisset X, Montcuquet A, Roux T, Maillart E, Lebrun-Frenay C. Vukusic S, et al. Mult Scler. 2023 Jan;29(1):37-51. doi: 10.1177/13524585221130934. Epub 2022 Nov 8. Mult Scler. 2023. PMID: 36345839 Review.
  • Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society.
    Lebrun C, Vukusic S; French Group for Recommendations in Multiple Sclerosis France4MS the Société francophone de la sclérose en plaques SFSEP; List of investigators. Lebrun C, et al. Rev Neurol (Paris). 2019 Jun;175(6):341-357. doi: 10.1016/j.neurol.2019.04.001. Epub 2019 Apr 27. Rev Neurol (Paris). 2019. PMID: 31036391
  • Urinary tract infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society.
    Donzé C, Papeix C, Lebrun-Frenay C; French Group for Recommendations in Multiple Sclerosis (France4MS); Société francophone de la sclérose en plaques (SFSEP); SPILF; Co-chairs; Supervision of the readers; Readers; Rating group; Reading group. Donzé C, et al. Rev Neurol (Paris). 2020 Dec;176(10):804-822. doi: 10.1016/j.neurol.2020.02.011. Epub 2020 Sep 5. Rev Neurol (Paris). 2020. PMID: 32900473
See all similar articles

Cited by

MeSH terms

Substances

LinkOut - more resources